Annovis Bio Actively Recruiting Patients for its Phase 2a Trials in Alzheimer’s and Parkinson’s Diseases
August 20 2020 - 6:45AM
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug
platform company addressing Alzheimer’s disease (AD), Parkinson’s
disease (PD) and other neurodegenerative diseases, is pleased to
announce it has restarted patient recruitment for its Phase 2a
clinical trial in AD which was suspended due to COVID-19 in March
2020, and initiated recruitment for its new Phase 2a clinical trial
in AD and PD.
The Company’s first Phase 2a trial of its lead
compound, ANVS401, is a one-month study in 24 AD patients conducted
in collaboration with the Alzheimer Disease Cooperative Study. The
study is being conducted in six sites, including the University of
California, San Diego, Johns Hopkins, Indiana University,
Washington University, Cleveland Clinic, and Columbia University.
Prior to suspension of enrollment, 14 patients had been enrolled
and treated in this trial; patient 15 is expected to be enrolled at
the end of August. Data from this trial is expected in 2021.
The second Phase 2a trial is a one-month study
that will treat 14 AD and 14 PD patients at 15 sites across
the US. Initial data from this trial is expected in early 2021.
This study will be followed by a dose response study in 40 PD
patients, and the Company expects the final readout by late summer
2021.
“We are excited to be able to recruit patients
for both of our Phase 2a trials,” commented Maria Maccecchini,
Ph.D., CEO of Annovis Bio. “We have increased the number of trial
sites to expedite enrollment and to deliver on our projections as
to when we would report data. We look forward to doing so as early
as January 2021.”
By fall, the Company also expects to report
final data from its NIH-funded long-term toxicology studies, which
should further confirm the safety of ANVS401 that has previously
been demonstrated in Phase 1 and earlier toxicology studies.
About Annovis Bio
Headquartered in Berwyn, Pennsylvania, Annovis
Bio, Inc. (Annovis) is a clinical-stage, drug platform company
addressing neurodegeneration, such as Alzheimer’s disease (AD),
Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS).
We believe that we are the only company developing a drug for AD,
PD and AD-DS that inhibits more than one neurotoxic protein and,
thereby, improves the information highway of the nerve cell, known
as axonal transport. When this information flow is impaired, the
nerve cell gets sick and dies. We expect our treatment to improve
memory loss and dementia associated with AD and AD-DS, as well as
body and brain function in PD. We have an ongoing Phase 2a study in
AD patients and have commenced a second Phase 2a study in AD and PD
patients. For more information on Annovis, please visit the
company’s website: www.annovisbio.com.
Forward-Looking Statements
Statements in this press release contain
“forward-looking statements” that are subject to substantial risks
and uncertainties. Forward-looking statements contained in this
press release may be identified by the use of words such as
“anticipate,” “expect,” “believe,” “will,” “may,” “should,”
“estimate,” “project,” “outlook,” “forecast” or other similar
words, and include, without limitation, statements regarding the
timing, effectiveness and anticipated results of ANVS401 clinical
trials and the approval of any allowances or additional patents.
Forward-looking statements are based on Annovis Bio, Inc.’s current
expectations and are subject to inherent uncertainties, risks and
assumptions that are difficult to predict. Further, certain
forward-looking statements are based on assumptions as to future
events that may not prove to be accurate. These and other risks and
uncertainties are described more fully in the section titled “Risk
Factors” in the Annual Report on Form 10-K for the year ended
December 31, 2019 filed with the Securities and Exchange
Commission. Forward-looking statements contained in this
announcement are made as of this date, and Annovis Bio, Inc.
undertakes no duty to update such information except as required
under applicable law.
Investor Relations:
Dave Gentry, CEO RedChip Companies Inc. 407-491-4498
Dave@redchip.com
SOURCE: Annovis Bio, Inc.
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Apr 2023 to Apr 2024